X

Bristol-Myers Squibb Company (BMY) Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release

Newsdesk: